Insider Trading Alert - BMY, ACN, REGN, ACAS And MXIM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 4, 2014, 131 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $408.12 to $109,651,973.50.

Highlighted Stocks Traded by Insiders:

Bristol-Myers Squibb Company (BMY) - FREE Research Report

Cornelius James M who is Director at Bristol-Myers Squibb Company sold 100,000 shares at $48.90 on Feb. 4, 2014. Following this transaction, the Director owned 373,393 shares meaning that the stake was reduced by 21.12% with the 100,000-share transaction.

The shares most recently traded at $48.15, down $0.75, or 1.56% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:

  • 24-Week # shares sold: 100,000

The average volume for Bristol-Myers Squibb Company has been 8.2 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $80.1 billion and is part of the health care sector and drugs industry. Shares are down 7.92% year-to-date as of the close of trading on Tuesday.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. The stock currently has a dividend yield of 2.96%. The company has a P/E ratio of 26.7. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMY - FREE

TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Accenture PLC Class A (ACN) - FREE Research Report

Casati Gianfranco who is Group Chief Exec-Growth Mkts at Accenture PLC Class A sold 3,392 shares at $78.19 on Feb. 4, 2014. Following this transaction, the Group Chief Exec-Growth Mkts owned 10,177 shares meaning that the stake was reduced by 25% with the 3,392-share transaction.

The shares most recently traded at $78.05, down $0.14, or 0.18% since the insider transaction. Historical insider transactions for Accenture PLC Class A go as follows:

  • 4-Week # shares sold: 9,248
  • 12-Week # shares sold: 56,205
  • 24-Week # shares sold: 71,205

The average volume for Accenture PLC Class A has been 3.3 million shares per day over the past 30 days. Accenture PLC Class A has a market cap of $49.7 billion and is part of the technology sector and computer software & services industry. Shares are down 5.04% year-to-date as of the close of trading on Tuesday.

Accenture plc provides management consulting, technology, and business process outsourcing (BPO) services worldwide. The company operates through Communications, Media & Technology; Financial Services; Health & Public Service; Products; and Resources segments. The stock currently has a dividend yield of 2.38%. The company has a P/E ratio of 15.6. Currently there are 9 analysts that rate Accenture PLC Class A a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACN - FREE

TheStreet Quant Ratings rates Accenture PLC Class A as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Accenture PLC Class A Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 208,972 shares at $283.78 on Feb. 4, 2014. Following this transaction, the 10% Owner owned 16.2 million shares meaning that the stake was reduced by 1.31% with the 208,972-share transaction.

The shares most recently traded at $284.05, up $0.27, or 0.09% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 19,000

The average volume for Regeneron Pharmaceuticals has been 810,500 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $27.6 billion and is part of the health care sector and drugs industry. Shares are up 4.36% year-to-date as of the close of trading on Tuesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 39.7. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

American Capital (ACAS) - FREE Research Report

Flax Samuel Allan who is EVP, GC and Secretary at American Capital sold 852 shares at $15.40 on Feb. 4, 2014. Following this transaction, the EVP, GC and Secretary owned 414,285 shares meaning that the stake was reduced by 0.21% with the 852-share transaction.

The shares most recently traded at $15.20, down $0.20, or 1.32% since the insider transaction. Historical insider transactions for American Capital go as follows:

  • 4-Week # shares sold: 5,159
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 43,248
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 116,165

The average volume for American Capital has been 2.1 million shares per day over the past 30 days. American Capital has a market cap of $4.3 billion and is part of the financial sector and financial services industry. Shares are down 1.79% year-to-date as of the close of trading on Tuesday.

American Capital, Ltd. is a private equity and venture capital firm specializing in management and employee buyouts, leveraged finance, mezzanine, acquisition, recapitalization, middle market, and growth capital investments. The company has a P/E ratio of 24.0. Currently there are 2 analysts that rate American Capital a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACAS - FREE

TheStreet Quant Ratings rates American Capital as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full American Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Maxim Integrated Products (MXIM) - FREE Research Report

Doluca Tunc who is President, Ceo & Director at Maxim Integrated Products sold 4,000 shares at $30.10 on Feb. 4, 2014. Following this transaction, the President, Ceo & Director owned 1.2 million shares meaning that the stake was reduced by 0.34% with the 4,000-share transaction.

The shares most recently traded at $29.23, down $0.87, or 2.98% since the insider transaction. Historical insider transactions for Maxim Integrated Products go as follows:

  • 4-Week # shares sold: 20,166
  • 12-Week # shares sold: 25,166
  • 24-Week # shares sold: 52,812

The average volume for Maxim Integrated Products has been 3.2 million shares per day over the past 30 days. Maxim Integrated Products has a market cap of $8.4 billion and is part of the technology sector and electronics industry. Shares are up 7.03% year-to-date as of the close of trading on Tuesday.

Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. The stock currently has a dividend yield of 3.48%. The company has a P/E ratio of 22.3. Currently there are 7 analysts that rate Maxim Integrated Products a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MXIM - FREE

TheStreet Quant Ratings rates Maxim Integrated Products as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Maxim Integrated Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric